title: [Pleiotropic effects of sevelamer: a model of intestinal tract chelating agent].
abstract: The number of patients with chronic kidney disease (CKD) with its associated complications has increased dramatically worldwide in recent years. Therefore, many experimental and clinical studies have examined over the last decade the mechanisms involved, in order to explain the sharp increase in cardiovascular mortality. Hyperphosphatemia is a major problem in these patients especially at advanced stages of CKD, and it is associated with cardiovascular and mineral complications in these patients. Sevelamer is a phosphate binder that allows a better control of hyperphosphatemia, like other phosphate binder agents, but it has additional pleiotropic effects such as correcting certain abnormalities of lipid metabolism and clearance of several uremic toxins. These effects of sevelamer, restricted to the intestinal lumen, underline the importance of intestinal pathway in CKD and open the way to new therapeutic strategies for the management of the CKD and its complications.
authors: Inserm U-1088, UFR de médecine et de pharmacie, université de Picardie-Jules-Verne, 1, rue des Louvels, 80037 Amiens cedex, France; Service de néphrologie, université Paris Île-de-France ouest (UVSQ), hôpital Ambroise-Paré, 9, avenue Charles-de-Gaulle, 92104 Boulogne-Billancourt cedex, France. Electronic address: ziad.massy@apr.aphp.fr.
authors: Ziad A
authors: ZA
authors: Massy
authors: Inserm U-1088, UFR de médecine et de pharmacie, université de Picardie-Jules-Verne, 1, rue des Louvels, 80037 Amiens cedex, France; Unité de réanimation médicale, service de néphrologie, CHU d'Amiens, place Victor-Pauchet, 80054 Amiens cedex, France.
authors: Julien
authors: J
authors: Maizel
mesh_terms: D000818:Animals; D016723:Bone Remodeling / Q000187:drug effects; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control; D002614:Chelating Agents / Q000494:pharmacology* / Q000627:therapeutic use; D015913:Chelation Therapy; D004195:Disease Models, Animal; D004730:Endothelium, Vascular / Q000187:drug effects; D017127:Glycation End Products, Advanced / Q000378:metabolism; D006801:Humans; D054559:Hyperphosphatemia / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism; D007249:Inflammation / Q000188:drug therapy; D007408:Intestinal Absorption / Q000187:drug effects; D050356:Lipid Metabolism / Q000187:drug effects; D051379:Mice; D010758:Phosphorus; D016226:Phosphorus, Dietary / Q000493:pharmacokinetics*; D016032:Randomized Controlled Trials as Topic; D006435:Renal Dialysis / Q000009:adverse effects; D051436:Renal Insufficiency, Chronic / Q000150:complications / Q000628:therapy; D000069603:Sevelamer / Q000494:pharmacology* / Q000627:therapeutic use; D014118:Toxins, Biological / Q000378:metabolism; D014511:Uremia / Q000378:metabolism; D014527:Uric Acid / Q000378:metabolism
chemical_list: D002614:Chelating Agents; D017127:Glycation End Products, Advanced; D016226:Phosphorus, Dietary; D014118:Toxins, Biological; C026865:uremia middle molecule toxins; D014527:Uric Acid; D010758:Phosphorus; D000069603:Sevelamer
keywords: Chronic kidney disease; Chélateur du phosphate; Maladie rénale chronique; Phosphate; Phosphate binder